StockData
Corcept Therapeutics Inc logo

Corcept Therapeutics Inc (CORT) stock

CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30328% above fair value
$67.79−2.28 (-3.25%)

Close on Nov 18, 2026Market cap $7.33BP/E 161.4Yield –

Corcept Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Corcept Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $106.92M, down 40.8% year over year. For fiscal 2025 it was $141.79M, down 27.7% from the year before. Over ten years it grew 46.5% a year on average. The highest annual figure on record is $196.12M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$141.79M-27.7%
FY2024Dec 31, 2024$196.12M+55.0%
FY2023Dec 31, 2023$126.54M+5.5%
FY2022Dec 31, 2022$119.91M-28.4%
FY2021Dec 31, 2021$167.42M+11.1%
FY2020Dec 31, 2020$150.73M+11.6%
FY2019Dec 31, 2019$135.03M+17.0%
FY2018Dec 31, 2018$115.37M+90.6%
FY2017Dec 31, 2017$60.52M+232.6%
FY2016Dec 31, 2016$18.20M+484.5%
FY2015Dec 31, 2015$3.11M–
FY2014Dec 31, 2014-$27.55M–
FY2013Dec 31, 2013-$37.19M–
FY2012Dec 31, 2012-$36.17M–
FY2011Dec 31, 2011-$27.43M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$31.02M-29.9%
Q1 FY2026Mar 31, 2026-$16.97M-463.8%
Q4 FY2025Dec 31, 2025$38.40M-35.9%
Q3 FY2025Sep 30, 2025$54.48M-24.0%
Q2 FY2025Jun 30, 2025$44.24M+8.5%
Q1 FY2025Mar 31, 2025$4.67M-80.4%
Q4 FY2024Dec 31, 2024$59.94M+984.0%
Q3 FY2024Sep 30, 2024$71.66M+35.5%
Q2 FY2024Jun 30, 2024$40.77M-3.3%
Q1 FY2024Mar 31, 2024$23.76M-8.5%
Q4 FY2023Dec 31, 2023$5.53M-83.4%
Q3 FY2023Sep 30, 2023$52.87M+58.8%
Q2 FY2023Jun 30, 2023$42.18M+134.1%
Q1 FY2023Mar 31, 2023$25.96M-26.3%
Q4 FY2022Dec 31, 2022$33.36M-32.4%
Q3 FY2022Sep 30, 2022$33.30M-31.4%
Q2 FY2022Jun 30, 2022$18.02M-59.2%
Q1 FY2022Mar 31, 2022$35.24M+39.3%
Q4 FY2021Dec 31, 2021$49.36M+42.5%
Q3 FY2021Sep 30, 2021$48.55M+63.3%
Q2 FY2021Jun 30, 2021$44.22M-16.8%
Q1 FY2021Mar 31, 2021$25.30M-23.9%
Q4 FY2020Dec 31, 2020$34.64M-28.3%
Q3 FY2020Sep 30, 2020$29.73M-22.1%
Q2 FY2020Jun 30, 2020$53.14M+111.3%
Q1 FY2020Mar 31, 2020$33.23M+41.9%
Q4 FY2019Dec 31, 2019$48.32M+125.7%
Q3 FY2019Sep 30, 2019$38.14M-14.2%
Q2 FY2019Jun 30, 2019$25.15M+66.0%
Q1 FY2019Mar 31, 2019$23.42M-31.8%
Q4 FY2018Dec 31, 2018$21.41M-13.9%
Q3 FY2018Sep 30, 2018$44.46M+310.0%
Q2 FY2018Jun 30, 2018$15.15M-1.4%
Q1 FY2018Mar 31, 2018$34.35M+263.5%
Q4 FY2017Dec 31, 2017$24.85M+453.0%
Q3 FY2017Sep 30, 2017$10.84M+22.6%
Q2 FY2017Jun 30, 2017$15.37M–
Q1 FY2017Mar 31, 2017$9.45M–
Q4 FY2016Dec 31, 2016$4.49M–
Q3 FY2016Sep 30, 2016$8.85M–

More Corcept Therapeutics figures

See a number that looks wrong?